On May 12th, the biaseparations.com website will be retired and migrated tosartorius.com.Learn moreabout our combined offering today!
12Oct2023
A Time of Celebration, Expansion and a Richer Portfolio
10Oct2023
The Republic of Slovenia and the European Union Are Co-funding the Investment of a Solar Power Station From the Cohesion Fund
15Mar2023
Teknova and Sartorius BIA Separations Announce Collaboration to Address Critical Pain Point in Gene Therapy Process Development
2Feb2023
Sartorius BIA Separations and Arnav Biotech enter in collaboration to develop a mRNA synthesis and purification platform, supported with PATfix in-process analytical solution
22Nov2022
Sartorius BIA Separations and Exopharm sign joint research agreement to develop integrated technology for large-scale exosome production
25Oct2022
Downstream AAV Production: A Targeted Approach to improve Empty / Full capsid separation (a Case Study with Pharmaron)
22Jun2022
New Achievement: The best performing company in Slovenia
22Jun2022
Thank you for attending Monolith Summer Symposium!
1Apr2022
BIA Separations (Sartorius) is now part of new EIC Pathfinder project Yscript
3Nov2021
BioNet and Sartorius’ company BIA Separations collaborate on production process development of mRNA vaccines
29Jun2021
Introduction of speCIMen
22Mar2021
Sartorius Creates a Premium Gene Therapy and Vaccine Portfolio With the Acquisition of BIA Separations